Chromatography ligand comprising domain c from Staphylococcus aureus protein a for antibody isolation

US12337293B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12337293-B2
Application numberUS-202217981262-A
CountryUS
Kind codeB2
Filing dateNov 4, 2022
Priority dateSep 29, 2006
Publication dateJun 24, 2025
Grant dateJun 24, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

First claim

Opening claim text (preview).

What is claimed is: 1. A chromatography ligand, which ligand comprises one or more Domain C units from Staphylococcus protein A (SpA), wherein the Domain C sequence has a sequence that is at least 94% identical to an amino acid sequence, the amino acid sequence being a sequence shown in SEQ ID NO:2 with mutation G25A. 2. The chromatography ligand according to claim 1 , wherein after 15 hours incubation in 0.5 M NaOH the ligand retains at least 80% of its binding capacity compared to the untreated ligand. 3. The chromatography ligand according to claim 1 , wherein after 15 hours incubation in 0.5 M NaOH the ligand retains at least 90% of its binding capacity compared to the untreated ligand. 4. The chromatography ligand according to claim 1 , wherein at least one asparagine in the sequence of the ligand is replaced with an amino acid other than glutamine or aspartic acid. 5. The chromatography ligand according to claim 1 , wherein the ligand is multimeric and comprises at least two Domain C mutants. 6. The chromatography ligand according to claim 1 , wherein the multimeric ligand comprises 2-8 Domain C units, optionally coupled via linker segments. 7. The chromatography ligand according to claim 1 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulfur atom(s). 8. The chromatography ligand according to claim 7 , wherein the terminal group comprises arginine or cysteine. 9. A separation matrix comprising the ligand of claim 1 . 10. The separation matrix according to claim 9 , wherein after 15 hours incubation in 0.5 M NaOH the ligand retains at least 80% of its binding capacity compared to the untreated ligand. 11. The separation matrix according to claim 9 , wherein after 15 hours incubation in 0.5 M NaOH the ligand retains at least 90% of its binding capacity compared to the untreated ligand. 12. The separation matrix according to claim 9 , wherein at least one asparagine in the sequence of the ligand is replaced with an amino acid other than glutamine or aspartic acid. 13. The separation matrix according to claim 9 , wherein the ligand is multimeric and comprises at least two Domain C mutants. 14. The separation matrix according to claim 9 , wherein the multimeric ligand comprises 2-8 Domain C units, optionally coupled via linker segments. 15. The separation matrix according to claim 9 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulfur atom(s). 16. The separation matrix according to claim 15 , wherein the terminal group comprises arginine or cysteine.

Assignees

Inventors

Classifications

  • the carrier being a carbohydrate · CPC title

  • Sorbents specially adapted for analytical or investigative chromatography · CPC title

  • Sorbents specially adapted for preparative chromatography · CPC title

  • Coatings on a core, the core being particle or fiber shaped, e.g. encapsulated particles, coated fibers · CPC title

  • involving a particular spacer or linking group, e.g. for attaching an active group · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12337293B2 cover?
The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling gro…
Who is the assignee on this patent?
Cytiva Bioprocess R & D Ab
What technology area does this patent fall under?
Primary CPC classification B01D15/3809. Mapped technology areas include Operations & Transport.
When was this patent published?
Publication date Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).